Celularity Inc

Celularity Inc. announced the appointment of Steven N. Gordon, Esq. as its Chief Operating and Administrative Officer, effective June 19, 2026. Concurrently, Mr. Gordon was also appointed to the Company's Board of Directors. Additionally, K. Harold Fletcher, Esq. was appointed as Chief Legal and Strategy Officer and Corporate Secretary, also effective June 19, 2026. Both officers have prior experience within the company in executive roles.

Celularity Inc. received a notice from Nasdaq on June 9, 2026, indicating non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company has been granted 180 calendar days, until December 7, 2026, to regain compliance. To do so, its market value must meet or exceed $35.0 million for a minimum of 10 consecutive business days. Celularity is evaluating options to address the deficiency, including potentially increasing its stockholders' equity.

Celularity Inc. announced the appointment of Rick Gonzalez as its new Chief Commercial Officer, effective May 29, 2026. Mr. Gonzalez will oversee global commercial strategy for the company's cenplacel-L and Lifebank platforms, reporting to CEO Robert J. Hariri. The company also provided a business update, highlighting its strategic focus on longevity and regenerative medicine, and mentioned the out-licensing of its biomaterials business to NexGel, Inc. for up to $30 million.

Celularity Inc. announced a Letter to Shareholders detailing strategic shifts, including the out-licensing of its biomaterials business to NexGel, Inc. for up to $30 million, which also eliminated nearly $13 million in liabilities. This move streamlines operations and refocuses resources on core placental-derived cellular therapy programs, particularly cenplacel-L, for longevity and age-related diseases. The company expects cenplacel-L revenue growth in 2026, driven by physician adoption in Florida, and has appointed Rick Gonzalez as Chief Commercial Officer to lead commercial expansion, while acknowledging a challenging capital environment.

Celularity Inc. announced it received a notification from Nasdaq on May 27, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This notification does not immediately impact the trading of its common stock. Nasdaq has given the company 60 days, until July 28, 2026, to submit a plan to regain compliance, with a potential extension until November 16, 2026. Celularity is working to file the 10-Q promptly.

Celularity Inc. entered into a Settlement Agreement with Helena Global Investment Opportunities 1 Ltd. on May 21, 2026, to resolve existing claims and restructure obligations. This follows Helena's prior notice of an event of default under a convertible promissory note. Under the agreement, Helena surrendered its Series A Convertible Preferred Stock, and Celularity committed to an immediate $500,000 cash payment, five subsequent monthly payments of $100,000 each, and the assignment of a $2,500,000 promissory note. The settlement aims to resolve financial disputes and clarify future obligations between the parties, with Helena's release of claims contingent on Celularity's fulfillment of these conditions.

Celularity Inc. announced it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and has regained compliance with Nasdaq Listing Rule 5250(c)(1). This resolves a previous non-compliance notification received on April 16, 2026, due to the delayed filing. The company also highlighted strategic actions, including out-licensing its biomaterials portfolio, realigning non-core personnel, and significantly reducing recorded liabilities by approximately $13 million, to strengthen its balance sheet and focus on core longevity and cell therapy platforms.

Celularity Inc. detailed its business strategy and operations in its annual 10-K filing, highlighting its focus on advancing health longevity through placental-derived allogeneic cellular therapies and advanced biomaterial products. The company also disclosed that it effected a 1-for-10 reverse stock split of its outstanding Class A common stock on February 28, 2024. Celularity continues to expand its biomaterials pipeline and leverage its integrated Celularity IMPACT platform for manufacturing and contract development services.

Celularity Inc. has issued a Convertible Promissory Note totaling $1,970,502.58 to Helena Special Opportunities LLC. The note, dated April 16, 2026, accrues interest at an annual rate of 18.0% and is set to mature on October 16, 2026. This financing arrangement provides the company with capital, albeit at a significant interest cost.

Celularity Inc. announced the closing of its transaction with NexGel, Inc., divesting its biomaterials product portfolio and licensing certain products. The deal provides Celularity with $13.3 million at closing, comprising $8.3 million in cash and a $5.0 million convertible note, plus potential future milestone payments up to $20.0 million and royalties. This strategic move aims to strengthen Celularity's balance sheet by retiring nearly $13.0 million of debt and allows the company to focus resources on its longevity-focused therapeutic pipeline.